PULMONARY FIBROSIS
Clinical trials for PULMONARY FIBROSIS explained in plain language.
Never miss a new study
Get alerted when new PULMONARY FIBROSIS trials appear
Sign up with your email to follow new studies for PULMONARY FIBROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug admilparant tested for long-term safety in lung scarring disease
Disease control Not yet recruitingThis study looks at the long-term safety of the drug admilparant in people with pulmonary fibrosis, a disease that scars the lungs. About 2,277 adults who finished earlier studies will take the drug and be monitored for side effects. The goal is to see if admilparant is safe to t…
Matched conditions: PULMONARY FIBROSIS
Phase: PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated May 17, 2026 02:02 UTC
-
New hope for lung scarring: drug combo trial launches
Disease control Not yet recruitingThis study tests adding a new drug, nerandomilast, to the standard treatment mycophenolate for people with pulmonary fibrosis (lung scarring). About 120 adults with various types of lung fibrosis will take the combo for 4 months. The main goal is to see if most patients can stay …
Matched conditions: PULMONARY FIBROSIS
Phase: PHASE4 • Sponsor: University of British Columbia • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
New PET scan could spot organ scarring without needles
Diagnosis Not yet recruitingThis study tests a new imaging method called 68Ga-1A12 PET to detect fibrosis (scarring) in organs like the lungs. It aims to provide a non-invasive alternative to biopsies for diagnosing and monitoring fibrosis. The study will enroll 50 adults suspected or confirmed to have fibr…
Matched conditions: PULMONARY FIBROSIS
Sponsor: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University • Aim: Diagnosis
Last updated May 17, 2026 02:17 UTC